15.46
price up icon1.24%   0.19
after-market 시간 외 거래: 15.25 -0.21 -1.36%
loading
전일 마감가:
$15.27
열려 있는:
$15.4
하루 거래량:
1.35M
Relative Volume:
0.47
시가총액:
$714.27M
수익:
$82.71M
순이익/손실:
$-102.24M
주가수익비율:
-4.2125
EPS:
-3.67
순현금흐름:
$-76.57M
1주 성능:
+6.69%
1개월 성능:
+5.53%
6개월 성능:
+51.72%
1년 성능:
-2.09%
1일 변동 폭
Value
$15.04
$15.66
1주일 범위
Value
$13.79
$15.80
52주 변동 폭
Value
$3.42
$17.00

Urogen Pharma Ltd Stock (URGN) Company Profile

Name
명칭
Urogen Pharma Ltd
Name
전화
972 9 770 7601
Name
주소
9 HA'TA'ASIYA ST, RA'ANANA
Name
직원
234
Name
트위터
@UroGenPharma
Name
다음 수익 날짜
2025-03-10
Name
최신 SEC 제출 서류
Name
URGN's Discussions on Twitter

URGN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
URGN
Urogen Pharma Ltd
15.46 668.10M 82.71M -102.24M -76.57M -3.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-16 업그레이드 H.C. Wainwright Neutral → Buy
2025-05-22 다운그레이드 H.C. Wainwright Buy → Neutral
2025-04-16 개시 Scotiabank Sector Outperform
2025-02-19 재개 Ladenburg Thalmann Buy
2024-08-22 개시 Guggenheim Buy
2023-02-08 다운그레이드 Jefferies Buy → Hold
2022-04-27 개시 Berenberg Buy
2020-04-16 재확인 H.C. Wainwright Buy
2020-04-13 재확인 H.C. Wainwright Buy
2020-01-09 개시 National Securities Neutral
2019-05-30 개시 JP Morgan Neutral
2019-05-29 개시 Goldman Neutral
2019-01-29 개시 H.C. Wainwright Buy
2018-11-08 재개 Jefferies Buy
2018-04-04 업그레이드 Raymond James Mkt Perform → Outperform
2018-01-02 개시 Ladenburg Thalmann Buy
2017-11-15 재확인 Oppenheimer Outperform
2017-11-15 다운그레이드 Raymond James Outperform → Mkt Perform
모두보기

Urogen Pharma Ltd 주식(URGN)의 최신 뉴스

pulisher
07:39 AM

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire

07:39 AM
pulisher
07:39 AM

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit - GlobeNewswire Inc.

07:39 AM
pulisher
03:38 AM

UroGen Pharma Ltd. Stock Analysis and ForecastFree High-Return Strategy Alerts - Autocar Professional

03:38 AM
pulisher
02:13 AM

INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire

02:13 AM
pulisher
11:25 AM

What analysts say about UroGen Pharma Ltd. stockTremendous growth potential - Autocar Professional

11:25 AM
pulisher
09:42 AM

UroGen Pharma Announces Data Of Phase 2b Of Bladder Cancer Study - Nasdaq

09:42 AM
pulisher
08:47 AM

UroGen Pharma (URGN) Reports Long-term Results for Bladder Cance - GuruFocus

08:47 AM
pulisher
08:16 AM

UroGen’s bladder cancer drug shows durable response in long-term study - Investing.com Australia

08:16 AM
pulisher
08:13 AM

UroGen Pharma Announces Long-Term Efficacy Results of ZUSDURI for Non-Muscle Invasive Bladder Cancer in Clinical Genitourinary Cancer Journal - Quiver Quantitative

08:13 AM
pulisher
08:02 AM

UroGen Announces Five-Year Long-Term Extension Study of the - GlobeNewswire

08:02 AM
pulisher
08:00 AM

Breakthrough: New Bladder Cancer Treatment Maintains Effectiveness for 3.5 Years Without Surgery - Stock Titan

08:00 AM
pulisher
Jul 20, 2025

What drives UroGen Pharma Ltd. stock priceBreakthrough financial growth - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

Is UroGen Pharma Ltd. a good long term investmentFree Stock Selection - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

2025-07-20 | URGN Shareholders Have Opportunity to Lead UroGen Pharma Ltd. Class Action LawsuitContact Bronstein, Gewirtz and Grossman, LLC Today! | NDAQ:URGN | Press Release - Stockhouse

Jul 20, 2025
pulisher
Jul 19, 2025

UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors - GlobeNewswire

Jul 19, 2025
pulisher
Jul 19, 2025

Urogen Pharma (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts - Defense World

Jul 19, 2025
pulisher
Jul 18, 2025

UroGen Bets Big On Gel-Based Cancer Treatments - Finimize

Jul 18, 2025
pulisher
Jul 17, 2025

URGN Class Action News: UroGen Pharma Ltd. Investors with - GlobeNewswire

Jul 17, 2025
pulisher
Jul 17, 2025

2025-07-17 | URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:URGN | Press Release - Stockhouse

Jul 17, 2025
pulisher
Jul 16, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming DeadlinesURGN - ETX View

Jul 16, 2025
pulisher
Jul 15, 2025

UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

What makes UroGen Pharma Ltd. stock price move sharplyBreakout Setup Scanner - beatles.ru

Jul 15, 2025
pulisher
Jul 14, 2025

2025-07-14 | URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! | NDAQ:URGN | Press Release - Stockhouse

Jul 14, 2025
pulisher
Jul 13, 2025

What UroGen Pharma Ltd.'s (NASDAQ:URGN) 84% Share Price Gain Is Not Telling You - 富途牛牛

Jul 13, 2025
pulisher
Jul 12, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Jul 12, 2025
pulisher
Jul 12, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm - GlobeNewswire

Jul 12, 2025
pulisher
Jul 12, 2025

Urogen Pharma's (URGN) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Jul 12, 2025
pulisher
Jul 11, 2025

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or - GlobeNewswire

Jul 11, 2025
pulisher
Jul 09, 2025

UroGen bladder cancer drug mitomycin wins FDA approval - MSN

Jul 09, 2025
pulisher
Jul 09, 2025

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - 富途牛牛

Jul 09, 2025
pulisher
Jul 08, 2025

UroGen Pharma stock holds Buy rating at H.C. Wainwright on Phase 3 trial progress By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

UroGen Pharma stock holds Buy rating at H.C. Wainwright on Phase 3 trial progress - Investing.com India

Jul 08, 2025
pulisher
Jul 08, 2025

UroGen concludes enrolment in Phase III trial of UGN-103 for bladder cancer - Yahoo Finance

Jul 08, 2025
pulisher
Jul 07, 2025

Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking - simplywall.st

Jul 07, 2025
pulisher
Jul 07, 2025

URGN: Analyst Reiterates Buy Rating with $25 Price Target | URGN Stock News - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen completes enrollment in phase 3 bladder cancer trial By Investing.com - Investing.com India

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | URGN Stock New - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen completes enrollment in phase 3 bladder cancer trial - Investing.com

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen Pharma Completes Patient Enrollment in Phase 3 UTOPIA Trial for UGN-103 in Bladder Cancer Treatment - Nasdaq

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times

Jul 07, 2025
pulisher
Jul 07, 2025

Breakthrough Bladder Cancer Drug Advances: 99 Patients Enrolled in Phase 3 Trial of Next-Gen Treatment - Stock Titan

Jul 07, 2025
pulisher
Jul 06, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen ... - Bluefield Daily Telegraph

Jul 06, 2025
pulisher
Jul 06, 2025

UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer - MSN

Jul 06, 2025
pulisher
Jul 05, 2025

11 Best Hot Stocks to Buy According to Wall Street Analysts - Insider Monkey

Jul 05, 2025

Urogen Pharma Ltd (URGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):